Wow. Thanks for providing links to the very impressive data for melanoma from the BRAF/MEK combination out of GSK. I see from the third link that there are discussions to move from phase I directly into phase III. I assume this synergistic effects of BRAF & MET inhibitors isn't something specific to the GSK drug combo, so don't you think this success will induce other companies to try their own combos?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.